Safety and performance confirmation study with dMD-003

Safety and performance confirmation study with dMD-003 - Study to evaluate the safety and performance of dMD-003 in patients scheduled to undergo planned two-stage hepatectomy -

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2032240323

Enrollment

Registered

2024-09-10

Start date

2024-11-19

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic liver cancer

Interventions

The study device (dMD-003) is applied, in principle, just under the wound (around the cut surface of the liver) immediately before wound closure in the initial surgery of a planned two-stage hepatecto

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with bilobar multiple liver metastasis from colon or rectal cancer who are eligible for a hepatectomy only if a planned two-stage hepatectomy is used. (2) Patients scheduled to undergo a second-stage hepatectomy at 2 to 12 weeks after the date of the initial hepatectomy. Other criteria.

Exclusion criteria

Exclusion criteria: (1) Patients scheduled to undergo open resection along with the initial hepatectomy in the case of a concurrent primary colon or rectal tumor. (2) Patients with a history of open surgery for a primary colon or rectal tumor. (3) Patients who have previously undergone open surgery of the liver, bile duct, or upper abdomen. Other criteria.

Design outcomes

Primary

Measure	Time frame
(1) Zuhlke classification (2) TORAD score	—

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-332256303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026